This article is more than 5 years old. Information may no longer be current.

Ribomic's wet AMD candidate shows positive phase 1/2a topline results

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A single dose of RBM-007, an oligonucleotide-based aptamer with anti-FGF2 activity, showed positive topline results in a phase 1/2a clinical trial in wet age-related macular degeneration patients, according to a press release.

RBM-007 (Ribomic) was well-tolerated and had no dose-limiting toxicities or systemic or ocular serious adverse events, and seven of nine patients treated showed evidence of RBM-007 bioactivity.

The open-label, dose escalation SUSHI study included nine subjects who had previously received anti-VEGF treatments. Subjects received a single injection of RBM-007 in three sequential dose cohorts, the release said.

“[The] SUSHI study has demonstrated that [a] single dose of intravitreal RBM-007 up to 2 mg dose is well-tolerated in subjects with wet AMD. We are pleased to demonstrate evidence of clinical efficacy in several subjects as measured by BCVA and OCT thickness, suggesting FGF2 is an important target in the pathogenesis of wet AMD,” Yusuf Ali, PhD, CEO of Ribomic USA, said in the release.